Di Stasi et al. previously showed that CD30CAR-Ts armored with CCR4 as a cognate receptor for CCL17 possess improved tumor homing and tumoricidal activity compared with CD30CAR-Ts that lack CCR4 [95]. This evidence concerns the gene CCR4 and neoplasm.